Drug Information

Drug (ID: DG01477) and It's Reported Resistant Information

• Name: Seliciclib
• Synonyms: Roscovitine; Seliciclib; 186692-46-6; R-Roscovitine; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; Seliciclib (Roscovitine); Roscovitine (Seliciclib,CYC202); UNII-0ES1C2KQ94; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; NSC-701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; MFCD02266401; NSC701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (2R)-2-{[6-(benzylamino)-9-(propan-2-yl)-9H-purin-2-yl]amino}butan-1-ol; RRC; C19H26N6O; Rosco; (2R)-2-{[6-(benzylamino)-9-(1-methylethyl)-9H-purin-2-yl]amino}butan-1-ol; (2R)-2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; Seliciclib [INN]; NSC 701554; 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; BMK1-E12; 1unl; 3ddq; (2R)-2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-1-butanol; 2a4l; BiomolKI_000048; 1-Butanol, (2R)-; ROSCOVITINE(Seliciclib); BiomolKI2_000054; M02443; CBiol_002016; Lopac0_001102; SCHEMBL94728; BSPBio_001078; KBioGR_000418; KBioSS_000418; MLS006011028; BDBM7533; cid_160355; GTPL6035; Roscovitine, >=98% (TLC); BCBcMAP01_000013; KBio2_000418; KBio2_002986; KBio2_005554; KBio3_000795; KBio3_000796; AOB2095; DTXSID20171928; EX-A052; BCPP000087; Bio1_000302; Bio1_000791; Bio1_001280; Bio2_000379; Bio2_000859; CC205; HMS1362F19; HMS1792F19; HMS1990F19; HMS3229N13; HMS3403F19; AMY10845; BCP01760; Roscovitine (Seliciclib, CYC202); ZINC1649340; HSCI1_000092; NSC800881; s1153; (2R)-2-((6-benzylamino-9-(propan-2-yl)-9h-purin-2-yl)amino)butan-1-ol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine; AKOS005146319; AC-2416; CCG-100652; DB06195; NSC-800881; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; IDI1_002134; Roscovitine - CAS 186692-46-6; SMP1_000266; 2,6,9-Trisubstituted purine deriv. 28; NCGC00094374-01; NCGC00094374-02; NCGC00094374-03; NCGC00094374-04; NCGC00094374-05; NCGC00094374-13; NCGC00094374-15; AS-56277; HY-30237; NCI60_036420; SMR004702823; SW220195-1; X7381; K00020; 692R466; A813074; J-011999; J-524224; Q3494619; BRD-K07691486-001-03-1; BRD-K07691486-001-05-6; UNII-AIR55KO85E component BTIHMVBBUGXLCJ-OAHLLOKOSA-N; (2R)-2-[[6-(benzylamino)-9-propan-2-yl-purin-2-yl]amino]butan-1-ol; (2R)-2-[[6-[(phenylmethyl)amino]-9-propan-2-yl-2-purinyl]amino]-1-butanol; (2R)-2-[[6-[(phenylmethyl)amino]-9-propan-2-yl-purin-2-yl]amino]butan-1-ol; (R)-2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-1-butanol; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (2R)-; 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (R)-; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]- 9H-purin-2-yl]amino]-(R)-1-butanol; Seliciclib; ; ; CYC-202; ; ; (2R)-2-[[6-(Benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol
• Indication:
  In total 3 Indication(s)
  Non-small-cell lung cancer [ICD-11: 2C25]; Phase 1; [1]
  Solid tumour/cancer [ICD-11: 2A00-2F9Z]; Phase 1; [1]
  Nasopharyngeal carcinoma [ICD-11: 2B6B]; Investigative; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Lung cancer [ICD-11: 2C25]; [1]
• Target: Cyclin-dependent kinase 2 (CDK2); CDK2_HUMAN; [1]
• Formula: 8
• IsoSMILES: CC[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3
• InChI: InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1
• InChIKey: BTIHMVBBUGXLCJ-OAHLLOKOSA-N
• PubChem CID: 160355
• ChEBI ID: CHEBI:45307
• VARIDT ID: DR1858
• INTEDE ID: DR01494
• DrugBank ID: DB06195

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Lung cancer [ICD-11: 2C25]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Cellular tumor antigen p53 (TP53) [1]

• Molecule Alteration: Missense mutation; p.P98A (c.292C>G)
• Resistant Disease: Lung adenocarcinoma [ICD-11: 2C25.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: H1299 cells; Lung; Homo sapiens (Human); CVCL_0060
• In Vitro Model: H1299 cells; Lung; Homo sapiens (Human); CVCL_0060
• Experiment for Molecule Alteration: Immunoblotting analysis
• Experiment for Drug Resistance: Cell death detection ELISA assay
• Mechanism Description: The missense mutation p.P98A (c.292C>G) in gene TP53 cause the resistance of Seliciclib by unusual activation of pro-survival pathway

Key Molecule: Cellular tumor antigen p53 (TP53) [1]

• Molecule Alteration: Missense mutation; p.A159V (c.476C>T)
• Resistant Disease: Lung adenocarcinoma [ICD-11: 2C25.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: H1299 cells; Lung; Homo sapiens (Human); CVCL_0060
• In Vitro Model: H1299 cells; Lung; Homo sapiens (Human); CVCL_0060
• Experiment for Molecule Alteration: Immunoblotting analysis
• Experiment for Drug Resistance: Cell death detection ELISA assay
• Mechanism Description: The missense mutation p.A159V (c.476C>T) in gene TP53 cause the resistance of Seliciclib by unusual activation of pro-survival pathway

Key Molecule: Cellular tumor antigen p53 (TP53) [1]

• Molecule Alteration: Missense mutation; p.R175H (c.524G>A)
• Resistant Disease: Lung adenocarcinoma [ICD-11: 2C25.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: H1299 cells; Lung; Homo sapiens (Human); CVCL_0060
• In Vitro Model: H1299 cells; Lung; Homo sapiens (Human); CVCL_0060
• Experiment for Molecule Alteration: Immunoblotting analysis
• Experiment for Drug Resistance: Cell death detection ELISA assay
• Mechanism Description: The missense mutation p.R175H (c.524G>A) in gene TP53 cause the resistance of Seliciclib by unusual activation of pro-survival pathway

Key Molecule: Cellular tumor antigen p53 (TP53) [1]

• Molecule Alteration: Missense mutation; p.S215G (c.643A>G)
• Resistant Disease: Lung adenocarcinoma [ICD-11: 2C25.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: H1299 cells; Lung; Homo sapiens (Human); CVCL_0060
• In Vitro Model: H1299 cells; Lung; Homo sapiens (Human); CVCL_0060
• Experiment for Molecule Alteration: Immunoblotting analysis
• Experiment for Drug Resistance: Cell death detection ELISA assay
• Mechanism Description: The missense mutation p.S215G (c.643A>G) in gene TP53 cause the resistance of Seliciclib by unusual activation of pro-survival pathway

Key Molecule: Cellular tumor antigen p53 (TP53) [1]

• Molecule Alteration: Missense mutation; p.Y220C (c.659A>G)
• Resistant Disease: Lung adenocarcinoma [ICD-11: 2C25.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: H1299 cells; Lung; Homo sapiens (Human); CVCL_0060
• In Vitro Model: H1299 cells; Lung; Homo sapiens (Human); CVCL_0060
• Experiment for Molecule Alteration: Immunoblotting analysis
• Experiment for Drug Resistance: Cell death detection ELISA assay
• Mechanism Description: The missense mutation p.Y220C (c.659A>G) in gene TP53 cause the resistance of Seliciclib by unusual activation of pro-survival pathway

Key Molecule: Cellular tumor antigen p53 (TP53) [1]

• Molecule Alteration: Missense mutation; p.Y234C (c.701A>G)
• Resistant Disease: Lung adenocarcinoma [ICD-11: 2C25.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: H1299 cells; Lung; Homo sapiens (Human); CVCL_0060
• In Vitro Model: H1299 cells; Lung; Homo sapiens (Human); CVCL_0060
• Experiment for Molecule Alteration: Immunoblotting analysis
• Experiment for Drug Resistance: Cell death detection ELISA assay
• Mechanism Description: The missense mutation p.Y234C (c.701A>G) in gene TP53 cause the resistance of Seliciclib by unusual activation of pro-survival pathway

References

• Ref 1: Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53Neoplasma. 2012;59(6):606-12. doi: 10.4149/neo_2012_077.